tiprankstipranks
Trending News
More News >
Capstone Therapeutics Corp (CAPS)
NASDAQ:CAPS
US Market

Capstone Therapeutics (CAPS) AI Stock Analysis

Compare
28 Followers

Top Page

CA

Capstone Therapeutics

(NASDAQ:CAPS)

Rating:40Underperform
Price Target:
$1.50
▼(-1.32%Downside)
Capstone Therapeutics is currently experiencing substantial financial and technical challenges. The negative P/E ratio and weak market momentum are significant concerns, coupled with declining revenue and profitability. Although there is some improvement in cash flow and potential financial flexibility from recent corporate actions, the overall outlook remains cautious.

Capstone Therapeutics (CAPS) vs. SPDR S&P 500 ETF (SPY)

Capstone Therapeutics Business Overview & Revenue Model

Company DescriptionCapstone Therapeutics (CAPS) is a biotechnology company focused on the development of novel therapies for the treatment of inflammatory and fibrotic diseases. The company operates within the pharmaceutical and healthcare sectors, leveraging its expertise in peptide-based therapeutics to address unmet medical needs. Capstone's core product offerings center around its proprietary drug candidates that are in various stages of clinical development.
How the Company Makes MoneyCapstone Therapeutics makes money primarily through the development and commercialization of its therapeutic drug candidates. The company's revenue model includes potential income from licensing agreements, partnerships with larger pharmaceutical companies, and eventual sales of approved drugs. Key revenue streams are often derived from upfront payments, milestone payments, and royalties from partners who license their drug candidates for further development and commercialization. Strategic partnerships and collaborations play a significant role in contributing to Capstone's earnings, providing both financial resources and expertise to advance their pipeline.

Capstone Therapeutics Financial Statement Overview

Summary
Capstone Therapeutics is facing financial challenges with declining revenue and profitability, negative equity, and high leverage posing substantial risks. Despite these issues, there is improvement in cash flow management with strong free cash flow growth, indicating effective cash management amidst ongoing net losses.
Income Statement
45
Neutral
Capstone Therapeutics has experienced declining revenue over the past few years, dropping from $61.56M in 2022 to $44.88M in 2024. Gross profit margin decreased from 26.9% in 2022 to 21.3% in 2024, indicating shrinking profitability. The company has posted net losses over the last two years, with a net loss margin of -12.2% in 2024, reflecting ongoing challenges in achieving profitability.
Balance Sheet
30
Negative
The company's balance sheet shows negative stockholders' equity of -$3.06M in 2024, a concerning sign of financial instability and potential risk. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, further indicating financial distress. These factors suggest significant leverage and financial risk.
Cash Flow
55
Neutral
Capstone has shown improvement in free cash flow from $1.24M in 2023 to $3.70M in 2024, showcasing strong free cash flow growth. The operating cash flow to net income ratio is favorable, though the company continues to face net losses. This implies effective cash management but highlights the need for sustained profitability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue43.42M44.88M48.35M61.56M66.74M45.45M
Gross Profit9.17M9.57M9.61M16.53M16.32M10.94M
EBITDA-910.00K-121.00K-1.75M4.23M5.02M2.64M
Net Income-3.88M-2.56M-3.82M2.31M3.92M10.46M
Balance Sheet
Total Assets35.50M47.22M52.70M65.21M60.85M54.87M
Cash, Cash Equivalents and Short-Term Investments1.74M11.00K52.00K23.00K50.00K1.00
Total Debt12.21M16.61M20.33M28.80M28.34M20.81M
Total Liabilities10.58M50.28M23.58M31.88M31.78M25.77M
Stockholders Equity26.97M-3.06M2.44M33.33M29.08M29.11M
Cash Flow
Free Cash Flow2.83M3.70M1.24M-3.06M2.55M639.00K
Operating Cash Flow2.85M3.82M1.45M-2.89M3.72M642.00K
Investing Cash Flow-20.00K-120.00K-208.00K-173.00K-931.00K-3.00K
Financing Cash Flow-1.11M-3.74M-1.21M3.04M-2.74M-697.00K

Capstone Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.52
Price Trends
50DMA
1.86
Negative
100DMA
2.26
Negative
200DMA
2.62
Negative
Market Momentum
MACD
-0.09
Positive
RSI
38.40
Neutral
STOCH
22.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPS, the sentiment is Negative. The current price of 1.52 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 1.86, and below the 200-day MA of 2.62, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 38.40 is Neutral, neither overbought nor oversold. The STOCH value of 22.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CAPS.

Capstone Therapeutics Risk Analysis

Capstone Therapeutics disclosed 18 risk factors in its most recent earnings report. Capstone Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Capstone Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (44)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
44
Neutral
C$976.20M-6.71-13.35%2.69%17.20%-32.62%
42
Neutral
$1.15M
-95.23%-325.89%
41
Neutral
$19.95M-160.26%19.21%
40
Underperform
$7.37M-11.56%-5.81%39.02%
36
Underperform
$12.01M-63.94%22.63%
34
Underperform
$7.59M-616.17%71.39%
ICICU
33
Underperform
$9.04M1475.93%75.26%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CAPS
Capstone Therapeutics
1.52
-2.98
-66.22%
AFMDQ
Affimed
0.05
-4.97
-99.00%
GOVX
GeoVax Labs
0.48
-2.32
-82.86%
RLMD
Relmada Therapeutics
0.60
-2.42
-80.13%
NXTC
NextCure
0.43
-1.06
-71.14%
ICU
SeaStar Medical Holding
0.56
-8.98
-94.13%

Capstone Therapeutics Corporate Events

M&A TransactionsBusiness Operations and Strategy
Capstone Therapeutics Releases Investor FAQ for Transparency
Neutral
Jun 30, 2025

On June 30, 2025, Capstone Holding Corp. announced the release of an Investor FAQ to provide shareholders with clear information on its growth strategy, capital structure, and M&A pipeline. The FAQ aims to enhance transparency and investor understanding of Capstone’s operations and long-term value creation, with plans for periodic updates as new developments occur.

Private Placements and Financing
Capstone Therapeutics Amends Stock Purchase Agreement
Positive
Jun 27, 2025

Capstone Holding Corp. entered into a common stock purchase agreement with an accredited investor on May 14, 2025, allowing the company to sell up to $20 million in common stock. On June 26, 2025, the company amended the agreement to increase the purchase limit per transaction to $3 million, potentially enhancing its financial flexibility and market operations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 02, 2025